217 related articles for article (PubMed ID: 18997174)
1. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Motiwala T; Majumder S; Ghoshal K; Kutay H; Datta J; Roy S; Lucas DM; Jacob ST
J Biol Chem; 2009 Jan; 284(1):455-464. PubMed ID: 18997174
[TBL] [Abstract][Full Text] [Related]
2. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
4. A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.
Seo JH; Wood LJ; Agarwal A; O'Hare T; Elsea CR; Griswold IJ; Deininger MW; Imamoto A; Druker BJ
Cancer Res; 2010 Sep; 70(18):7325-35. PubMed ID: 20807813
[TBL] [Abstract][Full Text] [Related]
5. CRKL binding to BCR-ABL and BCR-ABL transformation.
Kolibaba KS; Bhat A; Heaney C; Oda T; Druker BJ
Leuk Lymphoma; 1999 Mar; 33(1-2):119-26. PubMed ID: 10194128
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
8. Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.
Gao M; Huang ZL; Tao K; Xiao Q; Wang X; Cao WX; Xu M; Hu J; Feng WL
Oncotarget; 2017 Jan; 8(2):3304-3314. PubMed ID: 27926512
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
10. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
Qiu X; Guo G; Chen K; Kashiwada M; Druker BJ; Rothman PB; Chen JL
Neoplasia; 2012 Jun; 14(6):547-58. PubMed ID: 22787435
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
12. Jak2 is involved in c-Myc induction by Bcr-Abl.
Xie S; Lin H; Sun T; Arlinghaus RB
Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
[TBL] [Abstract][Full Text] [Related]
13. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
[TBL] [Abstract][Full Text] [Related]
14. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
Johnson KJ; Griswold IJ; O'Hare T; Corbin AS; Loriaux M; Deininger MW; Druker BJ
PLoS One; 2009 Oct; 4(10):e7439. PubMed ID: 19823681
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
18. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC
Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825
[TBL] [Abstract][Full Text] [Related]
19. The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
Mitra A; Sasikumar K; Parthasaradhi BV; Radha V
Biochim Biophys Acta; 2013 Jan; 1832(1):275-84. PubMed ID: 23124138
[TBL] [Abstract][Full Text] [Related]
20. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
